"Heart disease and stroke, which are the first and third leading causes of death for men and women, are among the most widespread and costly health problems facing the United States today, yet they also are among the most preventable. Cardiovascular diseases, including heart disease and stroke, account for more than one-third of all U.S. deaths – but that can change. Here at University Cardiology Associates, we are dedicated to helping prevent and treat heart and vascular disease. Our heart and vascular specialists use the latest in technology to put you on the road to recovery – that’s why University cares for more hearts than all other area hospitals combined"

During the past decade, University Cardiology Associates, LLC conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 3 clinical trials were completed, i.e. on average, 300% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University Cardiology Associates, LLC" #1 sponsor was "American Regent, Inc." with 1 trials, followed by "Astellas Pharma Global Development, Inc." with 1 trials sponsored, "Cardiovascular Clinical Science Foundation" with 1 trials sponsored, "Duke University" with 1 trials sponsored and "HealthCore-NERI" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University Cardiology Associates, LLC" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 2 trials as a collaborator, "Duke Clinical Research Institute" with 1 trials as a collaborator and "Massachusetts General Hospital" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "University Cardiology Associates, LLC" are "Heart Failure" (4 trials), "Coronary Artery Disease (CAD)" (1 trials), "Iron-deficiency" (1 trials) and "Pulmonary Hypertension" (1 trials). Many other conditions were trialed in "University Cardiology Associates, LLC" in a lesser frequency.

Most popular intervention types in "University Cardiology Associates, LLC" are "Drug" (4 trials), "Device" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Biomarker-guided care NT-proBNP" (1 trials), "Ferric Carboxymaltose" (1 trials), "Placebo" (1 trials), "Placebo for tadalafil" (1 trials) and "Regadenoson" (1 trials). Other intervention names were less common.

The vast majority of trials in "University Cardiology Associates, LLC" are 5 trials for "All" genders.

Currently, there are NaN active trials in "University Cardiology Associates, LLC". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in University Cardiology Associates, LLC, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in University Cardiology Associates, LLC, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".